---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-072308"
form_type: "8-K"
ticker: "IOVA"
cik: "0001425205"
company_name: "IOVANCE BIOTHERAPEUTICS, INC."
filed_at: "2023-06-16T23:59:59+00:00"
generated_at: "2026-06-13T22:30:08.769872+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Iovance enters $450M ATM equity offering with Jefferies, replaces prior program

## Summary
- Company entered new Open Market Sale Agreement with Jefferies for up to $450M in at-the-market common stock sales.
- Jefferies will receive commission of up to 3% of gross proceeds under the new program.
- Prior ATM agreement dated November 18, 2022 was terminated concurrently.
- Sales may be made through various methods including ordinary brokers' transactions on Nasdaq.

## SEC filing metadata
- accession: 0001104659-23-072308
- form_type: 8-K
- ticker: IOVA
- cik: 0001425205
- company_name: IOVANCE BIOTHERAPEUTICS, INC.
- filed_at: 2023-06-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 1.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1425205/000110465923072308/0001104659-23-072308-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1425205/000110465923072308/tm2318914d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-072308
- JSON: https://secwatch.observer/filing/0001104659-23-072308.json
- Plain text: https://secwatch.observer/filing/0001104659-23-072308.txt

## Key facts
- Material Agreements
  IOVANCE BIOTHERAPEUTICS, INC. entered into Sales Agreement with Jefferies LLC valued at up to $450.0 million (effective 2023-06-16).
  - Action: entry
  - Agreement: atm program
  - Counterparty: Jefferies LLC
  - Value: up to $450.0 million
  - Effective: 2023-06-16
  source text: On June 16, 2023, Iovance Biotherapeutics, Inc. (the “ Company ”) entered into a new Open Market Sale Agreement (the “ Sales Agreement ”) with Jefferies LLC (“ Jefferies ”) with respect to an at the market offering program, under which the Company may, from time to time in its sole discretion, issue and sell through Jefferies, acting as sales agent, up to $450.0 million of shares of the Company's common stock, par value $0.000041666 per share (the “ Common Shares ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1425205/000110465923072308/0001104659-23-072308-index.htm
- Material Agreements
  IOVANCE BIOTHERAPEUTICS, INC. terminated Prior Sales Agreement with Jefferies LLC (effective 2023-06-16).
  - Action: termination
  - Agreement: atm program
  - Counterparty: Jefferies LLC
  - Effective: 2023-06-16
  source text: On June 16, 2023, the Company terminated its Open Market Sale Agreement, dated November 18, 2022, with Jefferies (the “ Prior Sales Agreement ”) related to the offer and sale of shares of the Company's common stock in at-the-market offerings.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1425205/000110465923072308/0001104659-23-072308-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.